Radiosynthesis and Preclinical Evaluation of [F]F-DPA, A Novel Pyrazolo[1,5a]pyrimidine Acetamide TSPO Radioligand, in Healthy Sprague Dawley Rats by unknown
Mol Imaging Biol (2017)
DOI: 10.1007/s11307-016-1040-z
* The Author(s), 2017. This article is published with open access at Springerlink.com
RESEARCH ARTICLE
Radiosynthesis and Preclinical Evaluation
of [18F]F-DPA, A Novel Pyrazolo[1,5a]pyrimidine
Acetamide TSPO Radioligand, in Healthy
Sprague Dawley Rats
Thomas Keller,1 Anna Krzyczmonik,1 Sarita Forsback,1,2 Francisco R. López Picón,3,4
Anna K. Kirjavainen,1 Jatta Takkinen,3,4 Johan Rajander,5 Fanny Cacheux,6
Annelaure Damont,6 Frédéric Dollé,6 Juha O. Rinne,7 Merja Haaparanta-Solin,3,4
Olof Solin 1,2,5,8
1Radiopharmaceutical Chemistry Laboratory, Turku PET Centre, University of Turku, Turku, Finland
2Department of Chemistry, University of Turku, Turku, Finland
3PET Preclinical Imaging Laboratory, Turku PET Centre, University of Turku, Turku, Finland
4MediCity Research Laboratory, University of Turku, Turku, Finland
5Accelerator Laboratory, Turku PET Centre, Åbo Akademi University, Turku, Finland
6CEA, I2BM, Service Hospitalier Frédéric Joliot, Orsay, France
7Turku PET Centre, Division of Clinical Neurosciences, Turku University Hospital, Turku, Finland
8Turku PET Centre, University of Turku, Kiinamyllynkatu 4-8, 20520, Turku, Finland
Abstract
Purpose: Many neurological conditions result in the overexpression of the translocator protein
18 kDa (TSPO), today recognized as a biomarker for microglial activation and neuroinflamma-
tion imaging. The pyrazolo[1,5-a]pyrimidine acetamides are a particularly attractive class of
TSPO-specific ligands, prompting the development of several positron emission tomography
(PET) radiotracers. This includes F-DPA, a recently reported fluorinated ligand (Ki = 1.7 nM),
wherein the fluorine atom is directly linked to the phenyl moiety without the presence of an alkyl
or alkoxy spacer chain. Reported here is the preparation of [18F]F-DPA using [18F]Selectfluor
bis(triflate) and the preliminary evaluation of [18F]F-DPA in healthy rats. Its metabolic profile and
biodistribution in rats are compared with that of [18F]DPA-714, a closely related structure.
Procedures: [18F]F-DPA was synthesized by electrophilic fluorination using [18F]Selectfluor
bis(triflate), [18F]DPA-714 was synthesized by conventional nucleophilic fluorination. The
biodistribution of both radiotracers was compared in Sprague Dawley rats. Radiometabolites
of both radiotracers in plasma and brain homogenates were analyzed by radioTLC.
Results: The radiochemical yield of [18F]F-DPA was 15 ± 3 % and the specific activity was 7.8 ±
0.4 GBq/μmol. The radiochemical purity exceeded 99 %. The in vivo time activity curves of
[18F]F-DPA demonstrate rapid entry into the brain and a concentration equilibrium at 20–30 min
after injection. The metabolic profiles at 90 min after radiotracer injection in the plasma show that
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unchanged [18F]F-DPA and [18F]DPA-714 account for 28.3 ± 6.4 and 11.1 ± 2.6 % of the
remaining radioactivity, respectively. In the brain, unchanged [18F]F-DPA accounts for 93.5 ±
2.8 % of the radioactivity; whereas for [18F]DPA-714, this value is 53.6 ± 1.6 %.
Conclusions: [18F]Selectfluor bis(triflate) was successfully used to label F-DPA with fluorine-18.
The labeling position on the aromatic moiety imparts a higher stability compared to [18F]DPA-
714 with regard to in vivo metabolism. [18F]F-DPA is a promising new radiotracer and warrants
further investigation in animal models of disease.
Key words: TSPO, Electrophilic fluorination, F-DPA, DPA-714, Pyrazolopyrimidine, Fluorine-18,
Neuroinflammation, Brain, PET, [18F]Selectfluor bis(triflate)
Introduction
The translocator protein 18 kDa (TSPO), localized on the
outer mitochondrial membrane [1], plays a crucial role in the
transport of cholesterol across the aqueous intermembrane
space into the mitochondrial matrix [2]. Within the mito-
chondrion, cholesterol is used in the synthesis of steroids
and creation of new mitochondrial membrane during cell
multiplication and repair.
In recent years, TSPO has gained much attention as a
biomarker for neuroinflammation and microglial activation
due to its overexpression within the brain of individuals
suffering from neurological conditions such as Alzheimer’s
disease, multiple sclerosis, stroke, and traumatic brain
injury [3]. In addition, the location of TSPO on the outer
mitochondrial membrane makes it an attractive and readily
accessible target for low molecular weight molecules. As a
result, numerous TSPO-specific ligands have been devel-
oped and radiolabeled for use in positron emission
tomography (PET) [4] and single photon emission com-
puted tomography [5]. One of the most significant ligands
for TSPO is the isoquinolinecarboxamide PK11195 (N-
butan-2-yl-1-(2-chlorophenyl)-N-methylisoquinoline-3-
carboxamide). It was first labeled with tritium in 1985 by
Inoue et al. [6] and later with carbon-11 by Camsonne
et al. [7]. Despite the high lipophilicity and slow wash out
of PK11195 compared to the second generation TSPO
ligands, [11C]PK11195 has not been phased out from the
clinical setting and still remains a standard which is
routinely used in the evaluation of novel TSPO-specific
PET ligands.
Since the discovery of PK11195, a range of motifs have
been identified as alternative TSPO ligands and labeled for
PET imaging. These include the atypical benzodiazepine
[11C]Ro5-4864 [8], the vinca alkaloid [11C]Vinpocetine
[9], dihydro-9H-purinacetamides (for example, N-benzyl-
N-e thyl-2-(7-[11C]methyl-8-oxo-2-phenylpurin-9-
y l )ace tamide , known as [1 1C]Emapuni l [10] ) ,
aryloxyanilides (such as [11C]PBR28 [11] and [18F]FEPPA
[12]), indoleacetamides (such as [18F]GE-180 [13] and
[11C]SSR180575 [14]), acetamidobenzoxazolones [15]
without forgetting pyrazolopyrimidines, and bioisoteric
structures (imidazopyridines, for example). The latter
classes indeed include an impressive list of PET-
radioligands, among them, the 5,7-dimethylpyrazolo[1,5-
a]pyrimidin-3-yl)acetamides [11C]DPA-713 [16],
[18F]DPA-714 [17], and [18F]PBR146 [18], and the 6-
c h l o r o - im i d a z o [ 1 , 2 - a ] p y r i d i n - 3 - y l ) a c e t am i d e s
[11C]CLINME [19], [18F]PBR102 [18] and [18F]PBR111
[20].
The use of the short-lived carbon-11 label (t1/2 = 20.4 min) in
the cases of [11C]CLINME and [11C]DPA-713 limits their use to
facilities with an on-site cyclotron.While the fluorine-18-labeled
tracers, [18F]PBR102, [18F]PBR111, [18F]PBR146, and
[18F]DPA-714, have good brain penetration and kinetics, their
main pitfall arises from their labeling positions. Metabolism of
these tracers results in cleavage of the radioactive label [21, 22]
and the formation of non-specifically binding radiometabolites.
Despite these shortcomings, the extensive use of these tracers in
both preclinical and clinical studies, together with the ongoing
development of more metabolically stable analogues [23, 24],
further underpins the importance of this motif.
The short half-life of C-11-labeled radiotracer can be both
advantageous as well as a drawback. Carbon-11-labeled
analogues of bioactive molecule can be produced without
modifying their structure. Additionally, the short half-life of
carbon-11 makes it possible to image a test subject multiple
times in one day. However, the short half-life also limits the
clinical applicability of these tracers due to the time required
for distribution to PET centers that do not have an on-site
cyclotron. Fluorine-18 chemistry for PET imaging has
attracted interest since the half-life of this radioisotope
(t1/2 = 109.8 min) is long enough to allow late-stage
reactions and purification to be performed. Additionally, a
single production batch can be used for multiple patients
provided that the radiotracer is stable with respect to
radiolysis. Finally, it is possible to transport fluorine-18-
labeled radiotracers to PET facilities that do not have an on-
site cyclotron. At the same time the radioisotope decays
quickly enough, like all short-lived emitters, that the body-
concentration of the radioisotope falls to zero in a matter of
hours. Due to the low energy (Eβmax = 0.634 MeV) of the
positrons emitted, imaging using fluorine-18-labeled radio-
tracers gives high resolution PET images, which is of
particular importance when imaging the brain and especially
at the preclinical stage in studies using small animals.
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N , N - D i e t h y l - 2 - ( 2 - ( 4 - f l u o r o p h e n y l ) - 5 , 7 -
dimethylpyrazolo[1,5-a]pyrimidin-3-yl)acetamide (F-DPA,
Fig. 1a, compound 2) is a fluorine-containing
pyrazolopyrimidine with a structure closely-related to
DPA-714, also showing a good affinity (Ki = 1.7 nM) and
selectivity (Ki CBR 9 1 μM) [25] towards the TSPO. In
compound 2, the alkoxy-chain bridging the phenyl group
and the fluorine atom has been removed, thus positioning the
fluorine directly on the phenyl moiety. As such, improved
metabolic stability of the radiotracer would be expected, and
notably, the formation of small fluorine-18-labeled
radiometabolites that enter the brain, poorer PET imaging
quality and restrained quantitative imaging, as demonstrated
for [18F]DPA-714 [21], should be avoided.
Reported herein is the use of a mild electrophilic [18F]fluo-
rination reagent, 1-(chloromethyl)-4-[18F]fluoro-1,4-
diazoniabicyclo[2.2.2]octane bis(triflate) ([18F]Selectfluor
bis(triflate)) [26] for the preparation of [18F]F-DPA, and the
evaluation of this radiotracer in healthy rats. The metabolic
profile and biodistribution of [18F]F-DPA were compared with
that of the closely-related radiotracer [18F]DPA-714.
Materials and Methods
Details of the chemicals and HPLC systems used during the
radiochemical syntheses are provided in the Supplementary
Material.
F-DPA, DPA-714, and Related Precursors for
Labeling
N,N-Diethyl-2-(2-(4-fluorophenyl)-5,7-dimethylpyrazolo[1,5-
a]pyrimidin-3-yl)acetamide (F-DPA, Fig. 1a, compound 2), N,N-
diethyl-2-(2-(4-(2-fluoroethoxy)phenyl)-5,7-dimethyl-pyrazolo[1,5-
α]pyrimidin-3-yl)acetamide (DPA-714, Fig. 1b, compound 4), and
N,N-diethyl-2-(2-(4-(2-tosylethoxy)phenyl)-5,7-dimethyl-
pyrazolo[1,5-α]pyrimidin-3-yl)acetamide (DPA-714 labeling
Fig. 1 Scheme showing radiochemical syntheses used for the preparation of both radiotracers. a Production of [18F]F2, the
attempted direct labeling reaction using the reagent, production of [18F]Selectfluor bis(triflate), and synthesis of [18F]F-DPA
using electrophilic fluorination. b Nucleophilic fluorination of [18F]DPA-714 using the conventional, no-carrier-added Kryptofix
222/K+[18F]F− complex.
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precursor, Fig. 1b, compound 3) were synthesized as described by
Damont et al. [25, 27]
N,N-Diethyl-2-(2-(4-(tributylstannyl)phenyl)-5,7-dimethyl-
pyrazolo[1,5-α]pyrimidin-3-yl)acetamide (F-DPA labeling precur-
sor, Fig. 1a, compound 1) was synthesized from N,N-diethyl-2-(2-
(4-iodophenyl)-5,7-dimethylpyrazolo[1,5-a]pyrimidin-3-
yl)acetamide according to the procedure described in the Supple-
mentary Material.
Radionuclide Production
Fluorine-18 was produced as [18F]fluoride via the 18O(p,n)18F
nuclear reaction on an 18O-18-enriched water target, a detailed
description is provided in the Supplementary Material.
Labeling Syntheses
[18F]F2 and [
18F]Selectfluor bis(triflate) syntheses[18F]F2 gas
was synthesized according to a similar procedure as described by
Bergman and Solin [28].
[18F]Selectfluor bis(triflate) was synthesized according to the
method reported by Teare et al. [25]. These procedures are
described in detail in the Supplementary Material.
Direct Labeling with [18F]F2
In initial labeling tests, [18F]F2 was bubbled through a solution of
N,N-diethyl-2-(2-(4-(tributylstannyl)phenyl)-5,7-dimethyl-
pyrazolo[1,5-α]pyrimidin-3-yl)acetamide (F-DPA labeling precur-
sor, 3.1 mg (4.9 μmol), Fig. 1a, compound 1) in freon-11 (CCl3F,
700 μl) or acetone-d6 (750 μl) with AgOTf (3 mg, 12 μmol) as an
additive.
Labeling with [18F]Selectfluor bis(triflate)
Further labeling tests were performed using [18F]Selectfluor
bis(triflate) synthesized from [18F]F2. For this, F-DPA labeling
precursor (compound 1, 2.6 ± 0.7 mg (4.1 ± 1.2 μmol)) and AgOTf
(2 equivalents) were added to typically 200 μl of [18F]Selectfluor
bis(triflate) in acetone-d6 (with a total radioactivity of 500 ±
13 MBq; Fig. 1a). The reaction mixture was stirred at 45 °C and
samples for HPLC analysis were taken after 15 and 60 min of
reaction.
Analytical HPLC was performed using a Merck Chromolith
Performance RP-18e (10 μm, 4.6 × 100 mm) column (Merck
KGaA, Darmstadt, Germany) with an isocratic eluent system
consisting of 70 % 0.025 M aq. NaH2PO4 (pH 3.5) and 30 %
CH3CN and a flow rate of 4 ml/min. Using these conditions,
[18F]F-DPA showed a 5.5 min retention time.
The effect of a higher concentration of reactants was also
investigated. For this, after the addition of the crude stock of
[18F]Selectfluor bis(triflate) (200 μl), half of the acetone was
evaporated under a helium flow. The reaction was also sampled at
15 and 30 min, and analyzed with HPLC using the conditions
previously mentioned. In each case, the [18F]F-DPA fraction
(retention time 5.5 min) was collected, the radioactivity of the
fraction measured and the radiochemical yield was calculated.
The conditions chosen for the production of [18F]F-DPA
batches for preclinical evaluation were as described above, with
double concentration of reagents and a reaction time of 15 min. 4.0
± 1.6 mg (6.4 ± 2.6 μmol) of F-DPA precursor for labeling were
used, together with the entire crude stock (7.5 ± 0.8 GBq) of the
[18F]Selectfluor bis(triflate) produced.
Preparative HPLC of the crude reaction mixture was also
performed, and this using a Waters X-Terra Prep RP18 (10 μm,
7.8 × 300 mm) column (Waters Corporation, Milford MA, USA)
and an isocratic eluent system consisting of 65 % 0.1 M aq.
CH3CO2NH4 and 35 % CH3CN, and a flow rate of 4 ml/min. Using
these conditions, [18F]F-DPA had a retention time of 22–23 min.
The fraction containing the product was collected, diluted with
water (25 ml), and passed over a Waters Sep-Pak Light tC18
cartridge (Waters Corporation, Milford, MA, USA), thereby
trapping the radioligand. The cartridge was then washed with water
(25 ml). [18F]F-DPA was finally eluted using ethanol (400 μl) and
further diluted with saline to give a 10 % ethanolic solution,
suitable for intravenous injection. Analysis of the [18F]F-DPA
batches was carried out using the same previously described
analytical HPLC system and conditions.
Production of [18F]DPA-714
[18F]DPA-714 was synthesized according to a procedure similar to
that previously described by James et al. [17]. The synthesis is
described in detail in the Supplementary Material.
Mass Spectroscopy
The crude product mixtures resulting from direct fluorination
reactions were analyzed by liquid chromatography coupled to mass
spectrometry (QTrap, Applied Biosystems MIDS SCIEX, Toronto,
Canada). The HPLC system used included a Merck Chromolith
Performance RP-18e (10 μm, 4.6 × 100 mm) column and an
isocratic eluent system consisting of 0.1 % aq. formic acid and
CH3CN (70:30), followed by a 50 % CH3CN wash. The flow rate
was constant at 4 ml/min.
Animals and Ethical Statement
The study was approved by the Regional State Administrative
Agency for Southern Finland (license number ESAVI/3899/
04.10.07/2013). Animal studies were performed on male Sprague
Dawley rats (total n = 36, [18F]DPA-714; n = 18, [18F]F-DPA; n =
18, weight 290 ± 30 g).
All animals were group-housed under standard conditions
(temperature 21 ± 3 °C, humidity 55 ± 15 %, lights on from 6:00
a.m. until 6:00 p.m.) at the Central Animal Laboratory, University
of Turku, Turku, Finland.
In Vivo PET/CT Imaging and Analysis of PET
Data
Rats were anesthetized with isoflurane/oxygen gas and injected
intravenously with [18F]F-DPA (31.4 ± 2.1 MBq, n = 4 SA at the
time of injection = 4.1 ± 0.4 GBq/μmol) for scanning by an Inveon
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multimodality PET/CT tomograph (Siemens Medical Solutions,
Knoxville, TN, USA). In order to prevent eye dryness, a few drops
of Oftagel (25 mg/g; Santen, Tampere, Finland) were applied to the
eyes of the animals. The scanner has a 12.7 cm axial field of view
(FOV) and 10 cm transaxial FOV generating images from 159
transaxial slices. The spatial resolution of the scanner is 1.4 mm
according to the manufacturer’s specifications. The animals were
scanned for 10 min with computed tomography (CT) for attenua-
tion correction and anatomical reference, and immediately after
that, the radiotracer was injected for a 60-min dynamic PET scan.
Frames were taken at the following intervals: 30 × 10, 15 × 60, 4 ×
300, and 2 × 600 s. Volume of interests (VOIs) were drawn over the
whole brain, heart, lung, liver, and kidneys using Inveon Research
Workplace Image Analysis software (Siemens Medical Solutions).
From the VOIs, time–activity curves (TACs) were obtained and the
uptake of [18F]F-DPA was expressed as percentage of injected dose
per milliliter of tissue (%inj. dose/ml).
Ex Vivo Biodistribution of [18F]F-DPA and
[18F]DPA-714
For biodistribution studies, the anesthetized animals were injected
with [18F]F-DPA (30.7 ± 1.5 MBq) or [18F]DPA-714 (29.0 ±
2.1 MBq). After sacrifice (5, 15, 30, 60, and 90 min after injection,
n = 3, for every time point and radiotracer), the blood was collected
into Li-heparin tubes and transcardial perfusion with saline was
conducted rapidly in order to eliminate the blood from the whole
body. Following this, the organs of the animals were collected,
individually weighed, and the radioactivity was measured using a
gamma counter (Wizard2 3 × 3″, PerkinElmer, Turku, Finland). The
decay-corrected radioactivity is reported as percentage of injected
dose per gram (%ID/g).
Plasma Protein Binding
For the plasma protein binding studies, the anesthetized animals
(n = 3 for each tracer) were injected with [18F]F-DPA (27.0 ±
5.1 MBq) or [18F]DPA-714 (29.8 ± 3.4 MBq). After 15 min, the
animals were sacrificed and the blood was collected into Li-heparin
tubes and centrifuged (3000×g, 10 min). A 10-μl aliquot of the
plasma was spotted onto a TLC plate; following this, the remaining
plasma was filtered by ultrafiltration using Microsep 30K Omega
(Pall Life Sciences, Mexico) with a cut-off of 30 kDa. A 10-μl
aliquot of the resulting supernatant was also spotted onto the TLC
plate. The plates were exposed onto an imaging plate (Fuji BAS
Imaging Plate TR2025, Fuji Photo Film Co., Ltd., Tokyo, Japan)
for approximately two half-lives of fluorine-18 (3.5 to 4 h). After
the exposure, the imaging plates were scanned using a BAS-5000
reader (Fuji, Japan) with a resolution of 50 μm and the saved
images were analyzed using TINA software (version 2.10 g,
Raytest, Isotopenmessgeräte, GmbH, Straubenhardt, Germany).
RadioTLC Analyses of [18F]F-DPA and
[18F]DPA-714 Radiometabolites
The blood samples were taken into Li-heparin tubes and centri-
fuged (3000×g, 10 min). The plasma was transferred to an
Eppendorf tube and the plasma proteins were precipitated by
addition of 1.5 parts of MeOH by volume. Following a further
centrifugation (12,000×g, 4 min), 20 μl of the supernatant was
spotted onto an aluminum-backed silica gel 60/Kieselguhr F254
TLC plate (EMD Millipore 1.05567.0001, Merck Millipore,
Darmstadt, Germany).
Brain samples from the cortex were homogenized with
approximately 200 μl of 1:1 v/v of MeOH and water; the mixture
was transferred to an Eppendorf tube and centrifuged (12,000×g,
4 min). An aliquot (20 μl) of the supernatant was spotted onto the
TLC plate.
The TLC plates were developed with a mixture of dichloro-
methane and methanol (9:1, v/v) for a distance of 6 cm. Following
this, the plates were exposed onto an imaging plate (Fuji BAS
Imaging Plate TR2025, Fuji Photo Film Co., Ltd., Tokyo, Japan)
for approximately two half-lives of fluorine-18 (3.5 to 4 h). After
the exposure, the imaging plates were scanned using a BAS-5000
reader (Fuji, Japan) with a resolution of 50 μm and the saved
images were analyzed using TINA software (version 2.10 g,
Raytest, Isotopenmessgeräte, GmbH, Straubenhardt, Germany).
Statistical Methods
The results are reported as means ± SD (n ≥ 3) or as individual
values (n G 3). All statistical analyses were performed using the
Graph-Pad Prism program (version 6.04; GraphPad Software).
Differences between the ex vivo blood activities (%ID/g) for the
two radiotracers were tested using the two-tailed unpaired t test.
Differences were considered statistically significant if the P value
was less than 0.05.
Results
Radiochemistry
Labeling of [18F]F-DPA was initially attempted directly
using the discharge-produced [18F]F2. However, when using
either freon-11 or acetone-d6 (with silver triflate) as the
solvent, [18F]F-DPA was not produced and only fluorine-18-
labeled, but still stannylated by-products were obtained.
Indeed, molecular ions with masses corresponding to mono,
di, tri, and tetra-fluorination of F-DPA’s precursor were
observed. However, the labeling positions in these products
could not be identified by LC/MS. [18F]Selectfluor
bis(triflate) was thus employed as an alternative [18F]fluori-
nating reagent, and optimized conditions for the synthesis of
[18F]F-DPA were determined as shown in Table 1.
For preclinical evaluation, a 15-min reaction time and a
double concentration of reactants were the conditions
selected. [18F]F-DPA was produced from 7.5 ± 0.8 GBq of
[18F]Selectfluor bis(triflate) in 15 ± 3 % radiochemical yield
(radioactivity of product, decay-corrected to end of bom-
bardment (EOB), collected from HPLC, expressed as a
percentage of the [18F]Selectfluor bis(triflate) radioactivity,
also decay-corrected to EOB). SA (decay-corrected to EOB
too) was 7.8 ± 0.5 GBq/μmol and the radiochemical purity
exceeded 99 %.
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[18F]DPA-714 was synthesized in 43 ± 7 % radiochemical
yield, relative to starting [18F]fluoride activity, with SA
greater than 1 TBq/μmol, and a radiochemical purity also
exceeding 99 %.
In Vivo PET/CT Imaging and Analysis of PET
data
In the whole-body in vivo representative distribution of
[18F]F-DPA in a Sprague Dawley (SD) rat (Fig. 2a, b), the
mean TACs for [18F]F-DPA demonstrated that the
radiotracer rapidly entered into the brain with an equilibrium
concentration reached at approximately 20–30 min after
injection (Fig. 2c). At the periphery, the in vivo TACs
showed that [18F]F-DPA was excreted via the hepatobiliary
pathway based on the high levels of F-18 radioactivity that
accumulated in the intestine.
Ex Vivo Biodistribution of [18F]F-DPA and
[18F]DPA-714
The full ex vivo biodistribution data for [18F]F-DPA and
[18F]DPA-714 in SD rats at 5, 15, 30, 60, and 90 min after
injection are given in Supplementary Table 1. Measure-
ment of the uptake of (a) [18F]F-DPA and (b) [18F]DPA-
714 in the brain, whole blood, plasma, and bone (Fig. 3)
showed that after the initial uptake, measured at 5 min,
there was no significant accumulation of radioactivity in
the bone with either of the radiotracers, which suggests
that [18F]F-DPA and [18F]DPA-714 are not rapidly
defluorinated in vivo. A clear wash-out of radioactivity
from the blood and brain was seen. In the case of [18F]F-
DPA, the blood radioactivity was significantly lower (P ≤
0.006) than that of [18F]DPA-714.
At the periphery, the highest levels of radioactivity for
both radiotracers were measured in the adrenal glands,










1 15 200 0.518 33
2 60 200 0.518 27
3 15 100 0.495 31
4 30 100 0.495 44
5 15 100 0.497 37
6 30 100 0.497 31
RCC radiochemical conversion, radioactivity of product fraction collected
from HPLC expressed as a percentage of the total injected activity (both
activities are decay-corrected to the EOB)
Fig. 2 Representative PET/CT images from a Sprague Dawley rat are summed at a 0–5 and b 40–60 min after injection of
[18F]F-DPA. c Time-activity curves of [18F]F-DPA obtained from VOIs in the whole brain, lungs, heart, liver, and kidneys. Mean ±
SD, n = 3.
T. Keller et al.: Radiosynthesis of [18F]F-DPA
spleen, heart, lungs, kidneys, and small intestine (Suppl.
Table 1).
Plasma Protein Binding
The plasma binding study showed that at 15 min after
injection of the tracers, the fraction of radioactivity unbound
to the plasma proteins is 6.6 ± 3.1 % in the case of [18F]F-
DPA while for [18F]DPA-714 the free radioactivity fraction
is 32.8 ± 8.8 %.
RadioTLC Analyses of [18F]F-DPA and
[18F]DPA-714 Radiometabolites
The radioTLC analyses of the plasma following radiotracer
injection demonstrated that there was a degree of metabo-
lism for both [18F]F-DPA and [18F]DPA-714 (Fig. 4).
[18F]F-DPA, retention factor (Rf) = 0.83, had two major
radiometabolites that were more polar than the parent
compound, with Rf values of 0.60 and 0.67 (Suppl. Fig. 1).
In the case of [18F]DPA-714, there were also two major
radiometabolites (Suppl. Fig. 2), one with a slightly lower Rf
value (Rf = 0.67) compared to the unchanged tracer (Rf =
0.78) and a second that did not move from the origin (Rf =
0). At 90 min after injection of [18F]F-DPA, 28.3 ± 6.4 % of
the radioactivity in the plasma could still be attributed to
unmetabolized [18F]F-DPA, while in the case of [18F]DPA-
714, at the same time point, the unchanged radiotracer
accounted for only 11.1 ± 2.6 % of the remaining radioac-
tivity (Fig. 4a). At 90 min after injection, 93.5 ± 2.8 % of the
radioactivity in the brain was attributed to unmetabolized
[18F]F-DPA, while for [18F]DPA-714, at the same time
point, only 53.6 ± 1.6 % of the radioactivity was still
associated with unmetabolized radiotracer (Fig. 4b, and
Suppl. Figs. 3 and 4).
Discussion
[18F]Selectfluor bis(triflate) can be easily produced from
[18F]F2 by bubbling it through a solution of the adequate
azoniabicyclo[2.2.2]octane triflate precursor. In addition to
being a milder electrophilic fluorination reagent, the use
[18F]Selectfluor bis(triflate) can allow for a longer reaction
time compared to direct [18F]F2 labeling, as well as heating
and stirring of the reaction mixture. A major advantage of
using [18F]Selectfluor bis(triflate) is also that this reagent is
compatible with temporary storage, and as such, crude
stocks can easily be split into smaller portions, allowing
multiple reactions to be carried out from a single batch of
Fig. 3 Measurement of the uptake of a [18F]F-DPA and b [18F]DPA-714 in the brain, blood, plasma, and bone derived from
ex vivo biodistribution data performed on Sprague Dawley rats (mean ± SD, n = 3 per time point).
Fig. 4 Comparison of the percentage of unchanged [18F]F-DPA and[18F]DPA-714 in Sprague Dawley rat a plasma and b brain,
measured by radioTLC, at different time points after radiotracer injection (n = 3 per time point).
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cyclotron-produced fluorine-18. Additionally, such crude
stocks can also be used without further purification since the
unlabeled Selectfluor bis(triflate) precursor and [18F]LiF
both present in the reagent solution do not interfere with
subsequent labeling reactions.
With respect to the use of [18F]Selectfluor bis(triflate), a
comparison of entries 1, 3, and 5 (Table 1) with 2, 4, and 6,
respectively, demonstrates that a longer reaction time did not
afford a higher conversion. Hence, following the initial test
conditions, a reaction time of 15 min and a double
concentration of the reagents were the conditions chosen
for the production of [18F]F-DPA batches for preclinical
evaluation.
When [18F]F2 was employed as the [
18F]fluorinating
reagent, multiple fluorinated products were observed. Interest-
ingly, none of the radiolabeled products were missing the
tributyl tin moiety. This finding shows that elemental fluorine
is far too reactive to carry out selective fluorination on this
relatively structurally complex derivative. The varying degrees
of fluorination observed suggest that there are multiple sites
within the F-DPA precursor molecule (compound 1 in Fig. 1)
that are susceptible to fluorination by elemental fluorine gas.
These may include ortho and meta positions of the para-
substituted phenyl ring as well as the amide moiety.
The radiometabolite analyses of plasma and brain
homogenates showed that [18F]F-DPA is more metabolically
stable than [18F]DPA-714 in rats. The Rf values for
radiometabolites of [18F]F-DPA are only slightly lower than
of the parent molecule, thereby suggesting that while these
metabolites are slightly more polar than [18F]F-DPA, they
may be structurally similar to the injected radiotracer. In the
case of [18F]DPA-714, the major metabolite appears at the
plate origin thereby suggesting that it is strongly different in
structure from the parent molecule. This metabolite in all
likelihood results from the cleavage of the fluoroethoxy
chain which generates [18F]fluoroacetaldehyde and subse-
quently [18F]fluoroacetate as previously described by
Peyronneau et al. [21]. While [18F]F-DPA is only slightly
more metabolically stable than [18F]DPA-714 in rat plasma
(Fig. 4a), in the brain, unmetabolized [18F]F-DPA accounts
for the majority of the remaining radioactivity at 90 min
after injection (Fig. 4b). This result suggests that the major
radiometabolites of [18F]F-DPA only poorly cross the blood-
brain barrier, and hence, should not contribute to non-
specific signals. While there is somewhat of a difference
between the metabolic profile of [18F]DPA-714 reported
here and with previously reported data [21, 29], this
difference may be explained by the differing analytical
methods used. While sometimes considered a less sensitive
analytical method, radioTLC allows the visualization of
entire radioactivity content of the sample, while radioHPLC
will only detect those radioactive products that elute from
column. Furthermore, the short time required to perform
radioTLC and the possibility to run multiple samples
simultaneously make it an attractive analytical method for
the sensitive analyses of low radioactivity samples.
While there is a large difference between the free and
plasma bound radioactivity fractions for [18F]F-DPA and
[18F]DPA-714 at 15 min after injection of the tracer, this
large difference between the two tracers can be explained in
terms of their respective metabolic routes. [18F]DPA-714 is
metabolized primarily by cleavage of the fluorine-18-
containing side chain [21]. [18F]F-DPA, on the other hand,
does not contain the fluorine-18-labeled side chain; hence,
the metabolism will give radiometabolites that are more
structurally similar to the parent molecule. These
radiometabolites would then bind to the plasma proteins in
a similar way as the unchanged [18F]F-DPA.
The fast clearance of non-specific uptake of radioactivity
in the brain also demonstrates that radiotracer concentration
equilibrium is reached rapidly. This is a favorable charac-
teristic since it means that a PET image of the rat brain can
be acquired 20–30 min after radiotracer injection. In
addition, when this result is combined with the findings of
the radiometabolite analysis of brain homogenate, it can be
seen that during this period, the percentage of radioactivity
of the unchanged tracer is greater than 95 %. Hence, a PET
image acquired during this period will correspond to the
specifically bound tracer and will not suffer from the
drawback of background signal resulting from non-
specifically bound radioactivity. The lack of increased
accumulation of radioactivity as a function of time in the
bone of the skull, indicating little defluorination of the
tracer, is a pleasing observation as it means that the PET
images of the brain will not be affected by spillover from the
signal in the bone.
While the results presented in this manuscript do not directly
address the issue of specificity of [18F]F-FDA binding to TSPO
in neuroinflammation, i.e., no competitive blockade study was
performed in an animal model with neuroinflammation, a high
uptake of [18F]F-FDA as well as [18F]F-FDA-714 can be seen,
as expected, in steroid-producing TSPO rich organs such as the
adrenals, liver, and kidneys in rat (see Suppl. Table 1), thereby,
suggesting the specificity of [18F]F-FDA in vivo. Furthermore,
both the affinity (Ki) and selectivity (Ki CBR) of the noval
tracer (Ki = 1.7 nM, Ki CBR 9 1 μM)[25] are comparable with
those of the routinely used [18F]F-FDA-174 [17] (Ki = 0.91 ±
0.08 nM, Ki CBR 9 1 μM) [24, 30, 31]. When this is combined
with the specific binding shown for [18F]F-FDA-174 [17], it
gives promise to [18F]F-FDA as a new TSPO ligand.
Conclusions
[18F]Selectfluor bis(triflate) was successfully used to intro-
duce fluorine-18 at the para-position of a 2-phenyl-
pyrazolo[1,5a]pyrimidine motif, leading to the synthesis of
[18F]F-DPA. As demonstrated herein, the binding of the
fluorine-18 atom directly to the aromatic ring is more
favorable with respect to in vivo metabolism and [18F]fluo-
ride release, when compared to the fluoroalkoxy derivative
[18F]DPA-714, where the fluorine-18 atom is bound to the
aromatic ring via the alkoxy linker.
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Due to the different labeling strategies adopted, there is a
greater than 100-fold difference between the SAs of the two
radiotracers (even though [18F]F-DPA is on the higher end
of the scale for SA achieved by electrophilic fluorination).
Despite this difference, the quality of the PET-data obtained
in vivo suggests that high SA is not a critical factor when
using a TSPO ligand belonging to the pyrazolopyrimidine
acetamide class. While a low SA may pose a problem in
terms of receptor occupancy for not very abundant receptors,
TSPO is an abundant target in neuroinflammation and a
sensitive indirect index of neuronal damage [32] that is
expressed throughout the whole brain, and hence, there
should not be an issue with the receptor occupancy in terms
of competition between the radioactively labeled and
unlabeled analogues, at least, in cases of high overexpres-
sion of TSPO.
The biodistributions of [18F]F-DPA and [18F]DPA-714
compare well to one another and the major difference
between these radiotracers stems mainly from their
respective metabolic profiles. Due to fast washout of
radioactivity, resulting in lower background signal of
non-specifically distributed radiometabolites and the high
proportion of unchanged [18F]F-DPA in the rat brain, this
novel radiotracer can provide better target-to-background
ratios than [18F]DPA-714. The results of this study show
that [18F]F-DPA is a promising TSPO radiotracer, and
hence, warrants further investigation in animal models of
disease.
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